AstraZeneca's Covid-19 vaccine 70.4% effective at preventing the infection
Results
of an interim analysis of the Phase III programme conducted by Oxford University with AZD1222,
peer-reviewed and published in The Lancet on Wednesday demonstrated that the
vaccine is safe and effective at preventing symptomatic COVID-19 and that it protects
against severe disease and hospitalisation.
The
interim analysis for efficacy was based on 11,636 participants accruing 131
symptomatic infections from the Phase III UK and Brazil trials conducted by
Oxford University.
As
announced on November 23, the primary efficacy endpoint of the programme
statistical plan, based on the pooling of two dosing regimens, showed that the
vaccine is 70.4 per cent effective at preventing symptomatic COVID-19 occurring
more than 14 days after receiving two doses of the vaccine. A secondary
efficacy endpoint of prevention of severe disease demonstrated no cases of
severe infections or hospitalisations in the vaccine group. Read More
Comments
Post a Comment